Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-PROTKT: vicadrostat plus empagliflozin versus placebo plus empagliflozin in adults with type 2 diabetes, hypertension, and established cardiovascular disease
CTR20253506Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vicadrostat, empagliflozin in type 2 diabetes mellitus (T2DM), hypertension (HTN), cardiac morbidity, sponsored by Boehringer Ingelheim. Started Oct 2025; status: active.
02
Drugs
vicadrostatempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on CTR20253506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253506.